Cytokinetics to Announce First Quarter Results on May 6, 2025

Company Overview - Cytokinetics is a specialty biopharmaceutical company with over 25 years of scientific innovation focused on creating a muscle biology franchise business aimed at optimizing muscle performance for patients with cardiac and other muscle dysfunction diseases [3] Upcoming Financial Results - Cytokinetics is scheduled to report its first quarter results on May 6, 2025, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates [1] Conference Call Details - The conference call will be available via webcast on Cytokinetics' website, and participants can also join by telephone after registering in advance [2] Product Development - Cytokinetics is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [3] - The company is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophy and other conditions [3]